Living-donor liver transplantation for fulminant hepatic failure in adult patients with a left-lobe graft

Surgery. 2002 Jan;131(1 Suppl):S182-9. doi: 10.1067/msy.2002.119574.

Abstract

Background: Living donors are practically the only source of organs in countries where the availability of cadaveric donors is severely restricted, such as Japan. A left-lobe graft, in which one third of the liver is donated, is therefore used for adult-to-adult living-donor liver transplantation (LDLT) in patients with fulminant hepatic failure (FHF).

Methods: Fifteen adult patients with FHF, ranging from 22 to 59 years of age, were treated with LDLT with a left-lobe graft. Preoperative encephalopathy was grade II in 2 patients, grade III in 4 patients, and grade IV in 9 patients. The graft volume (GV) ranged from 260 to 570 mL, thus corresponding to 23% to 54% of the recipients' standard liver volume (SLV). The patients were divided into 2 groups according to their GV/SLV: a medium-size graft group (GV/SLV > or =30%; group M, n = 11) and a small-size graft group (GV/SLV <30%; group S, n = 4). The effects of GV/SLV on graft function and survival were compared. Postoperative neurologic complications were also evaluated.

Results: The donors are all doing well. Twelve (80%) of the 15 recipients are still alive, with a follow-up period of from 3 to 43 months. No statistically significant differences were observed in the postoperative serum levels of bilirubin and alanine aminotransferase, prothrombin time, or frequency of postoperative complications between the 2 groups. The graft and patient survival rates were 75% (3/4) and 75% (3/4) in group S and 73% (8/11) and 82% (9/11) in group M, respectively. All patients who survived the perioperative period recovered without any neurologic sequelae.

Conclusions: The high success rate and low donor risk of LDLT may therefore justify its use for adult patients with FHF using a left-lobe graft.

Publication types

  • Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Alanine Transaminase / blood
  • Bilirubin / blood
  • Female
  • Follow-Up Studies
  • Hepatectomy / methods*
  • Humans
  • Liver Failure / mortality
  • Liver Failure / pathology
  • Liver Failure / surgery*
  • Liver Transplantation*
  • Living Donors
  • Male
  • Middle Aged
  • Postoperative Care
  • Postoperative Complications
  • Prothrombin Time
  • Treatment Outcome

Substances

  • Alanine Transaminase
  • Bilirubin